Synaptogenix, Inc.
A clinical-stage biopharmaceutical company focused on developing novel treatments for neurodegenerative diseases. The company is developing a product platform based on bryostatin-1, a potential treatment for Alzheimer's disease, and is also evaluating bryostatin for other neurodegenerative diseases, including fragile X syndrome, multiple sclerosis, stroke and traumatic brain injury. Delaware-based
Overview
Overview | |
|---|---|
Country | United States |
State | New York |
Employees | 5 |
Founded | 2012 |
Financials | |
|---|---|
Market Capitalization | 5.56M |
Revenue | |
Operating Income | -7.08M |
Operating Margin | |
Net Income | -12.23M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 3457 / 5373 |
Sector : Healthcare | 292 / 1144 |
Industry : Biotechnology | 73 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 5361 / 5565 |
Sector : Healthcare | 1084 / 1182 |
Industry : Biotechnology | 610 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 3570 / 5436 |
Sector : Healthcare | 385 / 1164 |
Industry : Biotechnology | 136 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 5131 / 5330 |
Sector : Healthcare | 1115 / 1174 |
Industry : Biotechnology | 618 / 667 |